<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>International Society on Thrombosis and Haemostasis</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Hemab presents data for HMB-002 in von Willebrand disease</title>
      <description>
        <![CDATA[Hemab ApS recently presented preclinical data on its human monoclonal antibody against von Willebrand factor (vWF), HMB-002, for the treatment of von Willebrand disease. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/721575</guid>
      <pubDate>Fri, 27 Jun 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721575-hemab-presents-data-for-hmb-002-in-von-willebrand-disease</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Immune/monoclonal-antibodies-mAb.webp?t=1697037919" type="image/jpeg" medium="image" fileSize="224582">
        <media:title type="plain">Art concept for monoclonal antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>Novo Nordisk’s Inno-8 improves clotting formation in hemophilia</title>
      <description>
        <![CDATA[Novo Nordisk A/S recently presented data regarding their antibody fragment Inno-8 for the potential treatment of hemophilia A. Inno-8 was characterized in vitro alone or in combination with hemostatic agents used for treating hemophilia A.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721551</guid>
      <pubDate>Thu, 26 Jun 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721551-novo-nordisks-inno-8-improves-clotting-formation-in-hemophilia</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Hematologic/Hemostasis-wound-clotting.webp?t=1734991639" type="image/jpeg" medium="image" fileSize="424212">
        <media:title type="plain">Illustration of blood vessel injury being repaired by red blood cells and platelets</media:title>
      </media:content>
    </item>
    <item>
      <title>SV-003 restores coagulation in the preclinical setting</title>
      <description>
        <![CDATA[Bispecific antibodies mimicking coagulation factor VIIIa (FVIIIa) have yielded successful results in the treatment of hemophilia A, but there remain some issues in regard to their production. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/721415</guid>
      <pubDate>Wed, 25 Jun 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721415-sv-003-restores-coagulation-in-the-preclinical-setting</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Hematologic/Hematologic-hemostasis-hemophilia-injury-wound-vessel.webp?t=1743196293" type="image/jpeg" medium="image" fileSize="543486">
        <media:title type="plain">Illustration of hole in vessel wall with repair process in progress</media:title>
      </media:content>
    </item>
    <item>
      <title>Antibody shows potential in thrombotic thrombocytopenic purpura</title>
      <description>
        <![CDATA[Von Willebrand factor (vWF) plays a crucial role in hemostasis, and elevated levels are associated with risk of thrombosis. Gain-of-function mutations in the C-domain of vWF are linked to an increased risk of thrombosis. Previous work has shown that disrupting cysteine-rich C-domain in vWF led to reduced platelet recruitment in a shear-dependent fashion, making it a promising target for pharmacology. Apollo Therapeutics Ltd. has presented data on antibodies targeting the C-domain of vWF, including AP-21 as antithrombotics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710162</guid>
      <pubDate>Mon, 08 Jul 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710162-antibody-shows-potential-in-thrombotic-thrombocytopenic-purpura</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Thrombosis-blood-clot.webp?t=1676651893" type="image/png" medium="image" fileSize="1702000">
        <media:title type="plain">Illustration of clot forming in blood vessel</media:title>
      </media:content>
    </item>
    <item>
      <title>SS-315 shows hemostatic effects in mice with hemophilia A</title>
      <description>
        <![CDATA[Beijing Gensciences Inc. has developed a FVIIIa-mimetic bispecific antibody named SS-315 for the treatment of hemophilia A. SS-315 was developed by targeting FX with its upper Fab arms and FIXa with its down-side scFv arms, respectively; the hemostatic potential of SS-315 was investigated in vitro and in vivo.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710108</guid>
      <pubDate>Thu, 04 Jul 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710108-ss-315-shows-hemostatic-effects-in-mice-with-hemophilia-a</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Hematologic/Hemophilia-bleeds.webp?t=1676044194" type="image/png" medium="image" fileSize="763266">
        <media:title type="plain">Illustration of blood vessel that isn't clotting due to hemophilia</media:title>
      </media:content>
    </item>
  </channel>
</rss>
